Jason Mast
Jason Mast is a general assignment reporter at STAT, focusing on the science behind new medicines and the systems that decide whether that science reaches patients. He joined STAT in 2022 after two years at Endpoints News. His work primarily covers topics related to medicine and health care, including drug development, regulatory decisions, and access to treatments.
Biography:
https://www.statnews.com/staff/jason-mast/
80%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
90%
Examples:
- Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. He joined STAT in 2022, after two years at Endpoints News.
Conflicts of Interest
75%
Examples:
- The author has a potential conflict of interest due to his employment history at STAT and Endpoints News.
Contradictions
85%
Examples:
- Frostbite usually affects the extremities, such as fingers and toes, but it can also occur on other parts of the body.
- Iloprost is a drug given intravenously for several hours a day over a little more than week that has been approved by the F.D.A to treat severe frostbite.
Deceptions
75%
Examples:
- The author claims that Aurlumyn could 'avert' the ravages of frostbite when it only delays them. This is an example of sensationalism and misrepresentation.
Recent Articles
Dr. Anthony Fauci's Memoir: A Renowned Public Health Figure's Reflections on Leading the NIAID
Broke On: Sunday, 16 June 2024Dr. Anthony Fauci, the esteemed public health expert and NIAID director, shares insights from his long career in his new memoir. New Drug Approved to Treat Severe Frostbite in Adults, but Experts Question Its Effectiveness and Need for It
Broke On: Sunday, 25 February 2024Frostbite is a serious condition that occurs when skin and underlying tissue are exposed to freezing temperatures, causing blood vessels to narrow and limiting blood flow. Iloprost, recently approved by the FDA for severe frostbite treatment in adults, works by opening blood vessels to improve circulation and limit inflammation. However, experts question the need for this drug as there is limited data on how many people suffer from severe enough frostbite to require it. The most severe cases of frostbite may still require amputations. AbbVie Acquires Neuroscience Drugmaker Cerevel Therapeutics for $8.7 Billion
Broke On: Wednesday, 06 December 2023AbbVie has acquired Cerevel Therapeutics for $8.7 billion. This is AbbVie's second billion-dollar acquisition in less than a week, following its purchase of Immunogen for $10 billion. Cerevel brings with it drugs such as Emraclidine, an experimental treatment for schizophrenia and Alzheimer's disease psychosis. The deal values Cerevel Therapeutics at $45 per share.